LMT503 First-in-human SAD, MAD, and FE Study

NCT05659953 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammatory Bowel Disease
Colitis, Ulcerative
Crohn Disease

Interventions

DRUG: LMT503
DRUG: Placebo

Sponsor

Lmito Therapeutics Inc.